S. Urwyler

发表

Exciting Times beyond the Brain: Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues

T. Dinan, J. Cryan, S. Urwyler, 2011, Pharmacological Reviews.

Discovery of NMDA Glycine Site Inhibitors from the Chemical Universe Database GDB

D. Bertrand, J. Reymond, S. Urwyler, 2008, ChemMedChem.

3-(aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB.

Jean-Louis Reymond, Sonia Bertrand, D. Bertrand, 2009, Bioorganic & medicinal chemistry letters.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

Roland Heckendorn, Hans Allgeier, Fabrizio Gasparini, 1999, Neuropharmacology.

Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit.

L. Prézeau, J. Pin, I. Brabet, 2000, Molecular pharmacology.

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.

Steven Whitebread, Yves P Auberson, Daniel Hoyer, 2007, Bioorganic & Medicinal Chemistry.

Design, synthesis and preliminary evaluation of novel 3'-substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors.

F. Gasparini, S. Urwyler, P. Flor, 2001, Bioorganic & medicinal chemistry letters.

Extracts from rhizomes of Cyperus articulatus (Cyperaceae) displace [3H]CGP39653 and [3H]glycine binding from cortical membranes and selectively inhibit NMDA receptor-mediated neurotransmission.

P. Herrling, S. Urwyler, E. Bum, 1996, Journal of ethnopharmacology.

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

S. Urwyler, W. Froestl, K. Lingenhoehl, 2012, Bioorganic & medicinal chemistry letters.

Uptake and metabolism of catecholamines in rat brain synaptosomes: studies on the contribution of monoamine oxidase.

S. Urwyler, J. von Wartburg, 1981, Biochemical pharmacology.

Biochemical and behavioural properties of clozapine

D. Coward, A. Imperato, S. Urwyler, 2004, Psychopharmacology.

Allosteric Modulators: The New Generation of GABA B Receptor Ligands

S. Urwyler, 2016 .

Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABAB receptors.

S. Urwyler, M. Pozza, J. Mosbacher, 2004, European journal of pharmacology.

Identification of Dopamine “D3′’ and “D4′’ Binding Sites, Labelled with [3H]2‐Amino‐6,7‐Dihydroxy‐ 1,2,3,4‐ Tetrahydronaphthalene, as High Agonist Affinity States of the D1 and D2 Dopamine Receptors, Respectively

S. Urwyler, R. Markstein, 1986, Journal of neurochemistry.

Ca 2 1 Requirement for High-Affinity g-Aminobutyric Acid ( GABA ) Binding at GABAB Receptors : Involvement of Serine 269 of the GABABR 1 Subunit

L. Prézeau, J. Pin, I. Brabet, 2000 .

ALTERATIONS IN NEUROTRANSMITTER FUNCTION DURING THE DEVELOPMENT OF ETHANOL TOLERANCE AND DEPENDENCE

B. Tabakoff, P. Hoffman, S. Urwyler, 1980, Acta psychiatrica Scandinavica. Supplementum.

(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.

D. Laurie, B. Sommer, F. Gasparini, 1999, The Journal of pharmacology and experimental therapeutics.

Syntheses of Biphenyl Analogues of AP7, a New Class of Competitive N‐Methyl‐D‐aspartate (NMDA) Receptor Antagonists

D. Lowe, S. Urwyler, P. Kipfer, 1995 .

Synthesis and N‐Methyl‐D‐aspartate (NMDA) Antagonist Properties of the Enantiomers of α‐Amino‐5‐(phosphonomethyl)[1,1′‐biphenyl]‐3‐propanoic Acid. Use of a New Chiral Glycine Derivative

P. Herrling, D. Seebach, D. Lowe, 1992 .

Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist

A. Picard, S. Urwyler, K. Lingenhoehl, 2017, ChemMedChem.

Studies on the subcellular localization of monoamine oxidase types A and B and its importance for the deamination of dopamine in the rat brain.

S. Urwyler, J. von Wartburg, 1980, Biochemical pharmacology.

Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.

D. Coward, S. Urwyler, A. Enz, 1990, The Journal of pharmacology and experimental therapeutics.

Stimulation of dopamine synthesis and release by morphine and D-ala2-D-leu5-enkephalin in the mouse striatum in vivo.

B. Tabakoff, S. Urwyler, 1981, Life sciences.

SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity

S. Urwyler, A. Jaton, R. Markstein, 2005, Journal of Neural Transmission.

N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of γ-Aminobutyric AcidB Receptor Function

S. Urwyler, W. Froestl, M. Pozza, 2003, Journal of Pharmacology and Experimental Therapeutics.

Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor antagonists—II. Pharmacological characterization in vivo

S. Urwyler, P. Jenner, G. Fricker, 1996, Neuropharmacology.

Opiate receptor function after acute and chronic ethanol exposure

B. Tabakoff, P. Hoffman, S. Urwyler, 1980 .

Inorganic iron complexes derived from the nitric oxide donor nitroprusside: competitive N-methyl-D-aspartate receptor antagonists with nanomolar affinity.

S. Urwyler, H. Neijt, M. Koller, 2001, Biochemical pharmacology.

Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties

S. Urwyler, D. Dupuis, Tina Gjoni, 2005, Neuropharmacology.

Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.

S. Urwyler, B. Bettler, W. Froestl, 2001, Molecular pharmacology.

Survival Signaling and Selective Neuroprotection Through Glutamatergic Transmission

M. Rudin, A. Sauter, G. Rogers, 2002, Experimental Neurology.

Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist--I. Pharmacological characterization in vitro.

D. Laurie, D. Lowe, S. Urwyler, 1996, Neuropharmacology.

Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity.

Y. Auberson, I. Vranesic, S. Urwyler, 2011, Bioorganic & medicinal chemistry letters.

Novel N-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006

S. Urwyler, M. Koller, 2010, Expert opinion on therapeutic patents.

Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization

S. Urwyler, Tina Gjoni, 2008, Neuropharmacology.

SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors

S. Urwyler, A. Jaton, R. Markstein, 2005, Journal of Neural Transmission.

Biochemical and pharmacological effects of fluperlapine on noradrenaline and acetylcholine systems in some rodent, bovine and crustacean preparations

P. Herrling, S. Urwyler, C. Rüdeberg, 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.

D. Coward, S. Urwyler, A. Enz, 1989, Psychopharmacology bulletin.

Ethanol Alters Kinetic Characteristics and Function of Striatal Morphine Receptors

B. Tabakoff, P. Hoffman, S. Urwyler, 1981, Journal of neurochemistry.

Biochemical and thermodynamic aspects of the binding of [3H]glycine to its strychnine-insensitive recognition site associated with the N-methyl-D-aspartate receptor complex.

S. Urwyler, C. Schneider, 1992, Biochemical pharmacology.

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release

S. Urwyler, K. Kaupmann, P. Waldmeier, 2008, Journal of Neural Transmission.

The positive allosteric modulator GS39783 enhances GABAB receptor‐mediated inhibition of cyclic AMP formation in rat striatum in vivo

S. Urwyler, S. Imobersteg, S. Desrayaud, 2006, Journal of neurochemistry.

Allosteric Modulation of GABAB Receptors

S. Urwyler, 2006 .

Allosteric Modulation of GABA B Receptors

S. Urwyler, 2006 .

Changes in the properties of allosteric and orthosteric GABAB receptor ligands after a continuous, desensitizing agonist pretreatment.

S. Urwyler, Tina Gjoni, 2009, European journal of pharmacology.

diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of -Aminobutyric Acid B Receptor Function

S. Urwyler, W. Froestl, M. Pozza, 2003 .

The pharmacology of SDZ EAA 494, a competitive NMDA antagonist

P. Kelly, M. Emre, S. Urwyler, 1994, Neurochemistry International.

Binding of 3H-spiperone and 3H-(−)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands

D. Coward, S. Urwyler, 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release

S. Urwyler, K. Kaupmann, P. Waldmeier, 2009, Journal of Neural Transmission.

Affinity Shifts Induced by Cations Do Not Reliably Predict the Agonistic or Antagonistic Nature of Ligands at Brain Dopamine Receptors

S. Urwyler, 1987, Journal of neurochemistry.

Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo.

M. Rudin, A. Sauter, S. Urwyler, 1996, Neuropharmacology.

Novel N-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006

S. Urwyler, M. Koller, 2010, Expert opinion on therapeutic patents.

Pharmacological Properties of SDZ 208-912: A Potential High Potency,Non-Classical Neuroleptic

S. Urwyler, Coward Dm, A. K. Dixon, 1988, Pharmacopsychiatry.

Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.

S. Urwyler, W. Froestl, K. Lingenhoehl, 2001, Molecular pharmacology.

6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylic acid is a relatively potent antagonist at NMDA and kainate receptors

P. Herrling, S. Urwyler, P. Frey, 1988, Neuroscience Letters.

Mono- and divalent cations modulate the affinities of brain D1 and D2 receptors for dopamine by a mechanism independent of receptor coupling to guanyl nucleotide binding proteins

S. Urwyler, 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

Alterations in opiate receptor function after chronic ethanol exposure.

B. Tabakoff, P. Hoffman, S. Urwyler, 1982, The Journal of pharmacology and experimental therapeutics.